Hinova Pharmaceuticals Inc Class A 688302
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- ¥30.68
- Day Range
- ¥31.56–36.50
- 52-Week Range
- ¥22.60–53.96
- Bid/Ask
- ¥35.90 / ¥35.95
- Market Cap
- ¥3.55 Bil
- Volume/Avg
- 4.0 Mil / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 181
- Website
- http://www.hinovapharma.com
Comparables
Valuation
|
Metric
|
688302
|
02509
|
02480
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.78 | 32.68 | 4.61 |
Price/Sales | — | 100.25 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
688302
|
02509
|
02480
|
|---|---|---|---|
Quick Ratio | 6.87 | 1.70 | 5.91 |
Current Ratio | 7.21 | 1.86 | 5.97 |
Interest Coverage | −249.96 | −18.42 | −333.17 |
Quick Ratio
688302
02509
02480
Profitability
|
Metric
|
688302
|
02509
|
02480
|
|---|---|---|---|
Return on Assets (Normalized) | −16.61% | −47.40% | −24.42% |
Return on Equity (Normalized) | −18.47% | −341.08% | −27.57% |
Return on Invested Capital (Normalized) | −18.79% | −56.34% | −27.46% |
Return on Assets
688302
02509
02480
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Mjmlhgfts | Hcmhb | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Klncgkr | Rkdwrq | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rccwykyyy | Rzjddnv | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cwmrsqzm | Qxmqwfy | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Kqzqcldz | Rywp | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Dnqvpyr | Jqt | $29.2 Bil | |||
| Moderna Inc
MRNA
| Rhlswqt | Ryl | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Snpnwsd | Zpxb | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ndblsfqq | Zmjsm | $13.2 Bil | |||
| Incyte Corp
INCY
| Tgctmswn | Mcytgmt | $13.0 Bil |
United States